FDA Approvals, Stock Price Updates, New Study Results, Conference Schedules and Partnerships - Research Report on Merck, Pharmacyclics, UnitedHealth Group, Medtronic, and AstraZeneca Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 29, 2013 NEW YORK, November 29, 2013 /PRNewswire/ -- . Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), Pharmacyclics, Inc. (NASDAQ: PCYC), UnitedHealth Group Inc. (NYSE: UNH), Medtronic, Inc. (NYSE: MDT) and AstraZeneca plc (ADR) (NYSE: AZN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Merck & Co., Inc. Research Report On November 26, 2013, Merck & Co., Inc. (Merck) announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL (posaconazole) 100 mg delayed-release tablets. According to the Company, NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second therapy. The Company also markets NOXAFIL (40 mg/mL) oral suspension, which is dosed three times daily. Merck informed that NOXAFIL delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/430d_MRK -- Pharmacyclics, Inc. Research Report On November 26, 2013, Pharmacyclics Inc.'s (Pharmacyclics) stock declined 0.70%, ending the day at $123.83. Over the previous three trading sessions, shares of Pharmacyclics declined 1.79% compared to the Nasdaq Composite which gained 1.22% during the same period. The Full Research Report on Pharmacyclics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/df74_PCYC -- UnitedHealth Group Inc. Research Report On November 25, 2013, UnitedHealth Group Inc. (UnitedHealth) announced the results of a new study "Scope-Of-Practice Laws For Nurse Practitioners Limit Cost Savings that can be Achieved in Retail Clinics," co-led by the Company's Center for Nursing advancement. According to UnitedHealth, the report shows that nurse practitioners (NPs) practicing in retail clinics have the potential to deliver significant cost savings when treating a range of common conditions, with the greatest savings occurring in states that allow NPs to practice independently. The Company added that the research did not show any erosion in quality, as measured through excess ER visits or hospitalizations following the use of the retail clinic, meaning cost savings can be realized without lowering the quality of care. Dawn Bazarko, D.N.P., M.P.H., R.N., Senior Vice President of the UnitedHealth Group Center for Nursing Advancement and Co-Author of the Study, said, "This study helps confirm a new reality in today's health system: all care providers must be allowed to fully use their skills and education to meet our nation's increasingly complex health care needs. As one of the nation's largest employers of nurses, UnitedHealth Group understands that this is especially important for nurse practitioners, who will continue to play a vital role in increasing access to affordable, high-quality care for everyone." The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/73e5_UNH -- Medtronic, Inc. Research Report On November 26, 2013, Medtronic, Inc. (Medtronic) announced that it will participate in the Piper Jaffray Healthcare Conference on December 3, 2013, in New York. The Company said that the Executive Vice President and President of Medtronic's Cardiac and Vascular Group, Mike Coyle, will make a presentation about the Company beginning at 1:30 p.m. ET (12:30 p.m. CT). A live audio webcast of the presentation will be available on the day of the conference, and can be accessed by clicking on the Investors link on the Company's website. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/bc94_MDT -- AstraZeneca plc (ADR) Research Report On November 19, 2013, AstraZeneca plc's (ADR) (AstraZeneca) announced that it has selected Herzog & de Meuron to design the Company's new center in the UK. AstraZeneca said that the site, to be located on the Cambridge Biomedical Campus (CBC), will be home to one of the three global strategic R&D central centers and the Company's corporate headquarters, with a workforce of approximately 2,000. AstraZeneca added that the previously announced £330 million investment in Cambridge will create a working environment that fosters innovation in one of the world's pre-eminent biosciences hotspots, ultimately helping AstraZeneca improve pipeline productivity. AstraZeneca expects approximately 400 employees, primarily scientists involved in research and development to move to Cambridge in 2014 and will be based across three temporary sites at the Melbourn Science Park, the Cambridge Science Park, and Granta Park. The Full Research Report on AstraZeneca plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/09cc_AZN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
FDA Approvals, Stock Price Updates, New Study Results, Conference Schedules and Partnerships - Research Report on Merck,
Press spacebar to pause and continue. Press esc to stop.